Serology in Coastal Ecuador Signals Ongoing Trachoma Transmission in Rural Villages
Children in rural Esmeraldas Province showed serologic patterns consistent with continuing trachoma transmission, while nearby Borbón fell into a more intermediate zone that still needs follow-up. The signal came from antibodies to Chlamydia trachomatis plasma membrane protein 3, a marker that can capture cumulative exposure even when clinical surveys are sparse or logistically difficult to repeat.
In a region where elimination programs depend on knowing whether transmission is still active, that distinction matters at the village level. Rural communities along the Santiago River basin did not merely show antibody positivity; they showed age-patterns and seroconversion rates that align with places where public health intervention is still warranted.
How the Cohort Data Were Assembled Across Urban and Rural Settings
The analysis drew from two serologic sources in Esmeraldas Province. One was the ECoMiD longitudinal birth cohort, which enrolled pregnant mothers during 2019–2022 across an urban-rural gradient that included Esmeraldas city, Borbón, four road-accessible communities, and four communities reached by the Santiago and Onzole Rivers. The second came from community-based annual serologic surveillance for arbovirus transmission, which included Borbón and multiple surrounding villages, with age-stratified sampling that oversampled children 2–14 years of age.
Investigators tested 2,801 dried blood spots from 1,243 children ages 0–15 years for Pgp3 IgG. The combined dataset was then grouped into Borbón, with 799 samples, and rural villages, with 2,002 samples. Esmeraldas city was excluded because it was not part of the arbovirus surveillance frame. The analytic strategy used a catalytic model with a constant force of infection to estimate seroconversion rates per 100 person-years, then compared those estimates against global trachoma serology distributions to estimate whether public health action was likely needed.
Serology became the decision tool because the antibody response persists after infection and can function as a population-level record of exposure. In settings where active eye examinations, microbiologic testing, and repeated household surveys are difficult to sustain, that approach can expose whether transmission has already faded or is still replenishing susceptible children.
Rural Communities Crossed the Action-Needed Threshold
The age-specific curves separated early. Pgp3 IgG seroprevalence rose sooner and to higher levels in rural villages than in Borbón, and the two groups converged only by 13 years of age. Overall seroprevalence in Borbón was 7.0% (95% CI 5.3%–9.0%; 56/799), but the rural communities ranged widely, from 0% in Colon de Onzole to 31% in Zancudo.
Among 401 children ages 1–5 years, the estimated seroconversion rate was 4.6 per 100 person-years overall. Borbón sat lower at 1.9 per 100 person-years, while rural villages reached 5.7 per 100 person-years. Those values were then mapped onto global distributions from 34 trachoma surveys. The probability that public health action was needed was 99.3% in rural villages, versus 32.0% in Borbón.
One number is especially hard to ignore: in rural villages, the probability that the seroconversion rate was at or below 2 per 100 person-years was 0%. In the same communities, the probability that the seroconversion rate was 4 per 100 person-years was 91.3%.
What the Antibody Pattern Means for Elimination Strategy
Trachoma remains a disease of repeated exposure, crowding, and inadequate access to water, sanitation, and hygiene. In that setting, a rising antibody signal in young children is not just a historical imprint; it suggests ongoing transmission in the age band where the infection reservoir is being renewed. When children convert early and repeatedly, the public health consequence is persistent exposure of households and schools to the same ecological and behavioral drivers that sustain ocular infection.
The rural signal fits with districts elsewhere where active trachoma has remained entrenched and intervention was required. It also supports the broader logic of trachoma elimination programs in the Americas, which have prioritized surveillance in the Amazon basin but now need to account for coastal Ecuador as well. Esmeraldas Province should be considered in that planning, especially because the serology points to transmission in rural communities rather than a uniform province-wide pattern.
Borbón deserves a different read. Its estimates were lower, but not low enough to dismiss continued monitoring. The 95% confidence interval crossed the intermediate zone between the thresholds used here, so Borbón sits between clearly intervention-free and clearly intervention-needed categories. In practical terms, this is the kind of place where one more round of standardized surveillance could determine whether local transmission is tapering or simply fluctuating around a persistent baseline.
Why Existing Serosurveys Can Carry Elimination Programs Further
This study shows how existing serosurveillance platforms can answer a trachoma question without launching a new standalone campaign from scratch. The investigators used a sample base that had already been assembled for other infectious disease surveillance, then applied a serologic framework that estimated the probability of needing action against trachoma. In regions with limited access and scattered settlements, that kind of reuse can stretch surveillance resources while still preserving epidemiologic signal.
The biological rationale is straightforward. Pgp3 IgG captures prior ocular exposure to C. trachomatis, and when the seroconversion rate is elevated in younger children, transmission is still feeding the next cohort. This is the demographic where blinding sequelae begin their long causal chain: repeated follicular inflammation, scarring, trichiasis, and the eventual threat to vision if intervention never arrives.
Two caveats keep the findings from being overinterpreted. The sampling was not based on a fully population-representative cluster design, and children ages 3–5 years may have been underrepresented, especially in Borbón. The study also did not pair serology with clinical trachoma grading or ocular pathogen testing. Without those paired measures, serology can indicate likely transmission intensity, but it cannot fully substitute for standardized baseline eye surveys.
A direct clinical next step is already clear: conduct standardized trachoma surveys in coastal Ecuador, including Esmeraldas Province, to document active disease and establish reference points for elimination tracking. Until that happens, the current data leave little room for complacency in rural communities, where the antibody signal is consistent with ongoing transmission and a high probability that public health action is still needed.